2018

Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; Real-life data from Turkey, a single center experience

The most common reason of anemia is iron deficiency. Oral iron preparations are the first and most preferred method of treatment of iron deficiency anemia (IDA). In cases where Hb levels need to be increased rapidly, intravenous iron treatment gives more favorable results. Ferric carboxymaltose (FCM) is the most recent formulation developed to reduce the problem of anaphylaxis and has reached a very wide usage rate in a short time. In this study, we wanted to show the efficacy and safety of this treatment in patients diagnosed with IDA and treated with FCM in our clinic. In this study, 103 patients older than 18 years old who were diagnosed with IDA and treated with FCM, in our clinic, between January 2020 and December 2020 were included in the study. A total of 103 patients were evaluated. In the tests performed one month and two months after FCM use, an increase was seen as the following; the median of hemoglobin (Hb) level was 2.6 and 3.7 gr/dL, the median of hematocrit (Hct) level was 6% and 10%, the median of transferrin saturation (TS) was 17% and 18%, and the median of ferritin level was 85 and 48 ng/mL, respectively. When the Hb, Hct, TS and ferritin values were compared basal and after FCM treatment, statistically significant increase was found (p

PDF

___

World Health Organization, Centers for Disease Control and Prevention. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. In: de Benoist B, McLean E, Egli I, Cogswell M, eds. Geneva: World Health Organization; 2008.
Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49:1573-8.
Rognoni C, Venturini S, Meregaglia M, et al. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised con trials. Clinical Drug Investigation. 2016;36:177–94.
Doron SG C, Should a search for iron deficiency be part of the regular screening in all patients, whether anemic or not?” J Hematol Thromboembolic Dis. 2014;2(05).
McLean E, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005,” Public Health Nutrition. 2009;12:444–54.
Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia,” Hemodialysis Inter. 2010;14:47–54.
Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting irondeficiency anemia: a review of randomized controlled trials across different indications. Arzneimittel-Forschung. 2010;60:386–98.
Gomollon F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs. 2013;73:1761-70.
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose:a review of its use in iron-deficiency. Drugs, 2009;69:739–56.
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062– 2068.
Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfus (Paris). 2014;54:306–15.
Brugnara C., Beris P. Iron therapy. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of erythropoiesis, erythrocytes and iron metabolism. Paris: European School of Haematology; 2009. p. 512–8.6.
Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–307.7.
Breyman C, Milman N, Meazzacasa A. Et al. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J. Perinat. Med. 2017;45:443–53
Lichtenstein GR, Onken JE. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal‑Related Iron‑Deficiency Anemia Versus Oral Iron. Digestive Diseases Sci. 2018;63:3009–19.
Nunes AR, Costa AP, Rocha SL, Oliveria AG. Efficacy and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency at a hospital outpatient clinic: a retrospective cohort study of real-world clinical practice. Anemia, 2017;3106890:7
Friedrisch JR, Cançado RD. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev bras hematol hemoter. 2015;37:400–5.
Ikuta K, Ito H, Takahashi K. Et al. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study. Int J Hematol. 2019;109:50-8.
Onken JE, Bregman DB, Harrington RA. Et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014;54:306-315.
Hussain I, Bhoyroo J, Butcher A. Et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia Volume 2013;169107:10
Rognoni C, Ortalda V, Biasi C. Et al. Economic evaluation of ferric carboxymaltose for the management of hemodialysis patients with iron deficiency anemia in Italy. Adv Ther. 2019;36:3253–64.